Premium
FDA approves first, only patch for adults with schizophrenia
Author(s) -
Canady Valerie A.
Publication year - 2019
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.32109
Subject(s) - food and drug administration , transdermal , asenapine , schizophrenia (object oriented programming) , medicine , atypical antipsychotic , transdermal patch , psychiatry , antipsychotic , pharmacology
The Food and Drug Administration (FDA) on Oct. 11 approved the Secuado (asenapine) transdermal system, an atypical antipsychotic medication used to treat adults with schizophrenia. Secuado is the first and only FDA‐approved transdermal system for schizophrenia, Noven Pharmaceuticals officials stated.